[HTML][HTML] Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe
T Barcina Lacosta, AG Vulto, A Turcu-Stiolica, I Huys… - BioDrugs, 2022 - Springer
Background To encourage the rational prescribing of biologics, payers across Europe have
experimented with the implementation of benefit-sharing programs. Benefit-sharing …
experimented with the implementation of benefit-sharing programs. Benefit-sharing …
[HTML][HTML] The economic impact of originator-to-biosimilar non-medical switching in the real-world setting: a systematic literature review
E Hillhouse, K Mathurin, J Bibeau, D Parison… - Advances in …, 2022 - Springer
Introduction To save costs to the healthcare system, forced non-medical switch (NMS)
policies that cut drug coverage for originator biologics and fund only less expensive …
policies that cut drug coverage for originator biologics and fund only less expensive …
[HTML][HTML] European stakeholder learnings regarding biosimilars: part II—improving biosimilar use in clinical practice
Background Despite the benefits biosimilars offer in terms of cost savings and patient
access, healthcare professionals and patients have been reluctant to use them. Next to …
access, healthcare professionals and patients have been reluctant to use them. Next to …
Potential cost implications of mandatory non‐medical switching policies for biologics for rheumatic conditions and inflammatory bowel disease in Canada
In 2018, TNFα inhibitors were the highest cost drug class for Canadian public drug
programs. In 2019, two Canadian provinces announced mandatory nonmedical switching …
programs. In 2019, two Canadian provinces announced mandatory nonmedical switching …
[HTML][HTML] Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing …
S Azuz, M Newton, D Bartels, BK Poulsen - European Journal of Clinical …, 2021 - Springer
Purpose The aim of this study was to describe the implementation and uptake of biosimilar
trastuzumab in Denmark compared with other European countries. Methods European data …
trastuzumab in Denmark compared with other European countries. Methods European data …
The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis
Effective patient-provider communication is crucial to promote shared decision-making.
However, it is unclear how to explain treatment changes to ensure patient acceptance, such …
However, it is unclear how to explain treatment changes to ensure patient acceptance, such …
Switching from biologic to biosimilar products: insight from an integrated health care system
B Bhardwaja, S Klocke, E Ekinci, A Jackson, S Kono… - BioDrugs, 2022 - Springer
Biologics are indicated for the treatment of a wide range of conditions and have transformed
care in several therapeutic areas; however, they are expensive for both health care systems …
care in several therapeutic areas; however, they are expensive for both health care systems …
Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015–2018)
I Agirrezabal, E Sánchez-Iriso, K Mandar… - Diabetes …, 2020 - Am Diabetes Assoc
BACKGROUND Lantus, the reference insulin glargine used for the treatment of diabetes,
lost its patent protection in 2014, opening the market to biosimilar competitors. OBJECTIVE …
lost its patent protection in 2014, opening the market to biosimilar competitors. OBJECTIVE …
[HTML][HTML] Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain
F Lobo, I Río-Álvarez - Pharmaceuticals, 2021 - mdpi.com
Incentives contribute to the proper functioning of the broader contracts that regulate the
relationships between health systems and professionals. Likewise, incentives are an …
relationships between health systems and professionals. Likewise, incentives are an …
Biosimilars in rheumatology
FC Araujo, J Goncalves, JE Fonseca - Pharmacological Research, 2019 - Elsevier
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory
rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However …
rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However …